BTK and B-cell chronic lymphocytic leukemia: Preliminary data from the first human studies of BTK degraders NX-2127 [10], BGB-16673 [11], and NX-5948 [87] demonstrated early efficacy in RR non-Hodgkin lymphoma, including R/R CLL.